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Abstract
Background: Bleeding after cardiac surgery requiring surgical reexploration and blood component transfusion is
associated with increased morbidity and mortality. Although prothrombin complex concentrate (PCC) has been
used satisfactorily in bleeding disorders, studies on its efficacy and safety after cardiopulmonary bypass are limited.
Methods: Between January 2005 and December 2013, 3454 consecutive cardiac surgery patients were included in
an observational study aimed at investigating the efficacy and safety of PCC as first-line coagulopathy treatment as
a replacement for fresh frozen plasma (FFP). Starting in January 2012, PCC was introduced as solely first-line treatment
for bleeding following cardiac surgery.
Results: After one-to-one propensity score–matched analysis, 225 pairs of patients receiving PCC (median dose
1500 IU) and FFP (median dose 2 U) were included. The use of PCC was associated with significantly decreased 24-h
post-operative blood loss (836 ± 1226 vs. 935 ± 583 ml, p < 0.0001). Propensity score–adjusted multivariate analysis
showed that PCC was associated with significantly lower risk of red blood cell (RBC) transfusions (odds ratio
[OR] 0.50; 95 % confidence interval [CI] 0.31–0.80), decreased amount of RBC units (β unstandardised coefficient −1.42,
95 % CI −2.06 to −0.77) and decreased risk of transfusion of more than 2 RBC units (OR 0.53, 95 % CI 0.38–0.73). Patients
receiving PCC had an increased risk of post-operative acute kidney injury (AKI) (OR 1.44, 95 % CI 1.02–2.05) and renal
replacement therapy (OR 3.35, 95 % CI 1.13–9.90). Hospital mortality was unaffected by PCC (OR 1.51, 95 % CI 0.84–2.72).
Conclusions: In the cardiac surgery setting, the use of PCC compared with FFP was associated with decreased
post-operative blood loss and RBC transfusion requirements. However, PCC administration may be associated
with a higher risk of post-operative AKI.
Background
Bleeding after cardiac surgery requiring surgical reex-
ploration and blood component transfusion is associated
with increased morbidity and mortality [1–4]. It is also
accompanied by increased rates of late mortality as well
as poorer functional outcomes, leading to a substantial
morbidity burden and medical costs [1–4]. Therefore,
several plasma-derived and recombinant coagulation fac-
tors have been tested and introduced for the treatment
of excessive bleeding and coagulopathy following cardiac
surgery [5–7]. Experimental and clinical studies have
recently documented an improved efficacy exerted by
prothrombin complex concentrates (PCC) in treating
bleeding disorders [8–15]. PCC offers a rapid method
for replacing vitamin K–dependent clotting factors and
restoring normal haemostasis in the context of over-
anticoagulation, being quicker to prepare than fresh fro-
zen plasma (FFP) and allowing administration without
warming [16–18]. Its administration also avoids the
volume overload usually associated with FFP, reducing
the incidence of blood transfusions and the risk of
transfusion-related acute lung injury [16–18]. In
addition, PCC also has a better safety profile than FFP
because of its viral inactivation, minimising the risk of
transmission of a variety of infective agents, including
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prions [16]. However, despite these potential advantages,
concerns about an increased risk of thrombogenic events
have been raised, and only a minority of studies have
investigated the use of PCCs in cardiac surgery. The
researchers in the majority of these studies reported the
use of PCC to treat severe coagulopathy in high risk
patients, to reverse the effect of oral anti-coagulants or
even to evaluate the effect of PCC on cardiopulmonary
bypass (CPB)–induced coagulopathy in experimental
models [7–15]. The purpose of the present study, there-
fore, was to investigate the safety and efficacy of PCC as
first-line treatment in coagulopathy in a consecutive
series of patients undergoing cardiac surgery.
Methods
Population
Between January 2005 and December 2013, all consecu-
tive patients undergoing isolated coronary artery bypass
graft (CABG), valve surgery (with or without concomi-
tant CABG) and proximal aortic procedures at Varese
University Hospital were included in this observational
study. Elective, urgent or emergency procedures were all
included. Off-pump CABG procedures, along with other
cardiac operations (cardiac tumour removal, left ven-
tricular remodelling, adult congenital cardiac operation,
post-infarction ventricular septal defect and free wall
rupture repairs), were not included. Patients who died
intra-operatively without blood product administration
were also excluded from the analysis. All data were
prospectively collected and recorded in computerised
database registries that remained consistent over the
study period [4, 19, 20]. Information about demographics,
co-morbidities, medical and surgical history, operative de-
tails and post-operative events during the hospital stay
were all registered. The study protocol was approved by
the local institutional review board (Comitato Etico Pro-
vinciale di Varese s.n. 07/04/2015). Patient consent was
waived due to the retrospective and observational nature
of the study.
Patient management
Pre-operative management, anaesthetic and surgical
techniques were standardised for all patients and have
been reported previously [4, 19, 20]. Generally, anti-
platelet drugs and anti-coagulation drugs were discon-
tinued on the day of hospitalisation (median 2 and 3 days
before surgery, respectively). Other medications were
routinely omitted on the day of the operation and
restarted on the first post-operative day, unless clinically
contraindicated. All surgical procedures were performed
through a median sternotomy approach, and CPB was
undertaken in standardised fashion, with cannulation of
the ascending aorta and right atrial or bicaval venous
cannulation. Intravenous heparin was dosed as 300 IU/
kg body weight, and the activated clotting time (ACT)
was maintained above 450 seconds. In addition, in all
these cases, tranexamic acid was intravenously adminis-
tered after the induction of anaesthesia until the end of
the operation (20 mg/kg for the first hour and 2 mg/kg
thereafter). After the CPB, the circulating heparin was
antagonised with protamine sulphate at a ratio of 1 mg
of protamine per 100 IU of heparin. A prolonged ACT
after surgery was treated with an additional dose of pro-
tamine sulphate. Generally, when visual inspection re-
vealed microvascular bleeding or an important blood
collection in the cardiotomy reservoir (generally 200 ml
after weaning from CPB), the patient received an assess-
ment of the haemostasis/coagulation profile through
thromboelastography (TEG; Haemoscope, Niles, IL) with
and without heparinase. Therefore, peri-operative need
for blood products, including FFP and platelets, was de-
termined on an individual basis. Transfusion was guided
by point-of-care thromboelastography, prothrombin and
activated partial thromboplastin times, and platelet
count. Homologous red blood cells (RBC) were intra-
operatively administered to maintain the haemoglobin
concentration >7 g/dl or the haematocrit higher than
20 % during CPB, whilst they were post-operatively
given when haemoglobin was <8 g/dl. Platelets were
transfused when their count was ≤60 × 109/L. Additional
blood product transfusions, however, were done at the
discretion of the individual surgeon or attending anaes-
thesiologist. Aprotinin or other haemostatic agents were
not used in this series. At the end of surgery, patients
were transferred to the intensive care unit (ICU) and
managed according to the unit protocols [4, 19, 20].
Outcome end-points and definitions
The primary end-point was the impact of PCC on hospital
mortality. Secondary end-points were the effect of PCC
on post-operative complications and blood transfusion
products.
Patients receiving PCC constituted the study group,
and PCC was administered intra-operatively before chest
closure or in the ICU within the first post-operative
hours. Uman Complex D.I. (Kedrion; Castelvecchio
Pascoli, Italy) was the sole PCC available in our institution,
and starting in January 2012 it constituted the first-line
therapy in coagulation management, replacing FFP. PCC
contains clotting factors II, IX and X and is subjected to
two steps of viral inactivation—first, solvent/detergent
treatment and then heat treatment (100 °C for 30 minute-
s)—and is supplied as 500 IU of factor IX (20 ml) in vials
[21]. Other analysed variables were defined as previously
described [4, 19, 20]. Generally, blood product transfu-
sions were counted by units. Haemorrhagic complications
accounted for the need for reexploration for bleeding or
cardiac tamponade. Generally, significant post-operative
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bleeding requiring surgical reexploration was defined
as >300 ml during the first hour, >250 ml during the
second hour, >200 ml during the third hour or a total
of 1000 ml or more during the first 6 h. However,
the decision regarding haemorrhagic reexploration
was made by the surgeon in charge. Chest tube outputs
were used as a measure of blood loss, and our analysis
was based on the total volume of loss during the first 24 h
of the patient’s stay in the ICU. Post-operative acute kid-
ney injury (AKI) was defined according to the consensus
RIFLE criteria (risk, injury, failure, loss of function, and
end-stage renal disease) using the maximal change in
serum creatinine and estimated glomerular filtration rate
during the first 7 post-operative days compared with pre-
operative baseline values [22].
Statistical analysis
Clinical data were prospectively recorded and tabulated
using Microsoft Excel software (Microsoft, Redmond,
WA, USA). Continuous data are reported as mean and
standard deviation or median and interquartile range
(IQR), as appropriate. Nominal variables were reported
as counts and percentages. Fisher’s exact test, χ2 test and
the Mann-Whitney U test were used for univariate ana-
lysis. No attempt to replace missing values was made.
Multivariate analysis was performed using logistic and
linear regression. The area under the receiver operating
characteristic (ROC) curve was used to represent the
regression probabilities.
Since January 2012, PCC has been used systematically
as first-line therapy in coagulation management, com-
pletely replacing FFP, and this PCC use was consistently
followed. Therefore, the PCC study group was matched
with the historical series of patients who received FFP
before this time point. Because the study groups (i.e., the
PCC and the FFP groups) significantly differed in a
number of baseline and operative variables, a propensity
score was calculated by logistic regression to estimate
the probability of being assigned to each of the study
treatments. The propensity score was calculated in a
non-parsimonious way, including all 31 pre-operative
and operative variables listed in Tables 1 and 2. The ob-
tained propensity score was used for adjusted analysis in
the overall series and for one-to-one propensity score
caliper matching. The caliper width chosen was 0.2
times the standard deviation of the logit of the propensity
score (i.e., 0.01). Propensity score was used as a covariate,
along with the treatment method, in the multivariate ana-
lysis model for each outcome end-point. After the propen-
sity score matching was performed, differences between
the two groups were assessed. Absolute standardised dif-
ferences were estimated to evaluate the pre-match and
post-match imbalance, and a standardised difference <0.1
was considered a negligible difference in the mean or
prevalence of a covariate between treatment groups (Fig. 1)
[23, 24]. Finally, the significance within the models was
evaluated with the Wald test, whereas the strength of the
association of variables with post-operative outcomes was
estimated by calculating the odds ratio (OR), the β unstan-
dardised coefficient and 95 % confidence intervals (CIs).
The model was calibrated using the Hosmer-Lemeshow
goodness-of-fit test, as well as residual diagnostics (devi-
ance and degrees of freedom of β values). Model discrim-
ination was evaluated by using the area under the ROC
curve. All tests were two-sided with the α level set at 0.05
for statistical significance. Statistical analysis was per-




Among the 3454 included patients (mean age 68.0 ±
10.8 years, 32.6 % females), 234 (6.8 %) received isolated
PCC, 680 (19.7 %) received isolated FFP and 57 (19.6 %)
were administered PCC with concomitant FFP. PCC
subjects received a median of 1500 IU (IQR 1500–
1500 IU), whereas only 38 (13.1 %) had >1500 IU of
PCC. The FFP group received a median of 2 FFP U (IQR
2–4 U). In the overall population, resternotomy for
bleeding was necessary in 205 patients (5.9 %) and 2067
(59.8 %) required RBC transfusions. Hospital mortality
accounted for 101 patients (2.9 %).
Group comparisons and outcomes
The two study groups showed significant imbalance in
the mean and prevalence of a number of baseline risk
factors and operative variables (Table 1). A standardised
difference ≥0.1 was pre-operatively observed in 13 of 31
baseline and operative covariates taken into account in
this analysis (Fig. 1). Major imbalances were docu-
mented in the prevalence of pre-operative use of war-
farin and aspirin, New York Heart Association classes III
and IV, diabetes, cerebrovascular disease, myocardial
infarction, isolated CABG, and emergency procedures.
However, the incidence of platelet transfusion was simi-
lar between the FFP and PCC groups (53.2 % vs. 58.4 %,
p = 0.137) (Table 3).
The unadjusted univariate analysis demonstrated that
the use of PCC was associated with a significantly lower
risk of post-operative need for an intra-aortic balloon
pump (p = 0.029) and inotropes (p = 0.007), as well as
with decreased post-operative blood loss (p < 0.001) and
need for RBC transfusions (overall use: p = 0.001; num-
ber of units transfused: p < 0.001; more than 2 U trans-
fused: p < 0.001). However, patients receiving the PCC
had an increased risk of post-operative AKI (31.3 % vs.
23.4 %, p = 0.010) and renal replacement therapy (RRT)
(3.1 % vs. 1.2 %, p = 0.037). Multivariate analysis
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Table 1 Baseline characteristics of patients with reference to PCC administration
Overall series Propensity score–matched pairs
No PCC (n = 680) PCC (n = 291) p Value Pre-match SD No PCC (n = 225) PCC (n = 225) p Value Post-match SD
Age, yr 69.8 ± 10.1 69.0 ± 12.3 0.963 0.006 69.7 ± 10.6 69.2 ± 11.6 0.932 0.004
Female sex 263 (38.7) 114 (39.2) 0.884 0.01 91 (40.4) 91 (40.4) 1.000 0
BMI, kg/m2 25.0 ± 4.5 25.4 ± 4.8 0.258 0.019 25.4 ± 4.9 25.0 ± 4.7 0.400 0.017
eGFR, ml/min/1.73 m2 61 ± 21 66 ± 26 0.003 0.009 64 ± 23 64 ± 26 0.878 0.001
Dialysis 14 (2.1) 7 (2.4) 0.734 0.02 3 (1.3) 6 (2.7) 0.503 0.1
Haematocrit, % 38 ± 6 37 ± 5 0.047 0.026 36 ± 6 37 ± 5 0.206 0.019
Haemoglobin, g/dl 12.4 ± 2.0 12.1 ± 1.9 0.002 0.075 11.8 ± 2.0 12.1 ± 1.9 0.128 0.085
Platelets, 109/L 210 ± 83 213 ± 79 0.552 0 216 ± 88 209 ± 74 0.418 0
Aspirin 279 (39.9) 69 (23.7) <0.0001 0.353 60 (26.7) 60 (26.7) 1.000 0
Clopidogrel 64 (9.4) 28 (9.6) 0.918 0.007 22 (9.8) 22 (9.8) 1.000 0
Warfarin 94 (13.8) 24 (8.2) 0.015 0.18 24 (10.7) 21 (9.3) 0.637 0.047
NYHA class III-IV 94 (13.8) 74 (25.4) <0.0001 0.295 42 (18.7) 44 (19.6) 0.810 0.023
Atrial fibrillation 145 (21.3) 62 (21.3) 0.995 0 49 (21.8) 50 (22.2) 0.909 0.01
Hypertension 379 (55.7) 194 (66.7) 0.002 0.227 143 (53.6) 142 (63.1) 0.922 0.194
Diabetes 152 (22.4) 42 (14.4) 0.005 0.208 37 (16.4) 36 (16.0) 0.898 0.011
Pulmonary disease 86 (12.6) 40 (13.7) 0.641 0.033 34 (15.1) 28 (12.4) 0.412 0.078
Dyslipidaemia 200 (29.4) 123 (42.3) <0.0001 0.271 85 (37.8) 83 (36.9) 0.845 0.019
Peripheral vascular disease 110 (16.2) 59 (20.3) 0.123 0.106 38 (16.9) 38 (16.9) 1.000 0
Cerebrovascular disease 63 (9.3) 48 (16.5) 0.001 0.216 26 (11.6) 30 (13.3) 0.568 0.052
Prior cardiac surgery 91 (13.4) 46 (15.8) 0.320 0.068 37 (16.4) 34 (15.1) 0.698 0.036
Myocardial infarction 185 (27.2) 48 (16.5) <0.0001 0.261 43 (19.1) 41 (18.2) 0.809 0.023
LVEF, % 52 ± 13 53 ± 11 0.106 0.01 53 ± 12 52 ± 11 0.796 0.002
Emergency 161 (23.7) 49 (16.8) 0.018 0.172 45 (20.0) 41 (18.2) 0.632 0.046
Pre-operative IABP 36 (5.3) 14 (4.8) 0.755 0.023 14 (6.2) 9 (4.0) 0.284 0.1
BMI body mass index, eGFR estimated glomerular filtration rate, IABP intra-aortic balloon pump, LVEF left ventricular ejection fraction, NYHA New York Heart Association,
PCC prothrombin complex concentrates, SD standard deviation
Continuous variables are reported as mean and standard deviation; nominal variables are reported as counts (percentages)
Table 2 Operative data of patients with reference to PCC administration
Overall series Propensity score–matched pairs
No PCC (n = 680) PCC (n = 291) p Value Pre-match SD No PCC (n = 225) PCC (n = 225) p Value Post-match SD
Type of surgery 0.009 0.901
Isolated CABG 173 (25.4) 47 (16.2) 0.228 39 (17.3) 36 (16.0) 0.035
Isolated valve surgery 226 (33.2) 113 (38.8) 0.117 92 (40.9) 88 (39.1) 0.037
Valve surgery + CABG 154 (22.6) 64 (22.0) 0.014 47 (20.9) 53 (23.6) 0.065
Aortic surgery 127 (18.7) 67 (23.0) 0.106 47 (20.9) 48 (21.3) 0.01
CPB time, min 152 ± 64 148 ± 64 0.234 0.001 150 ± 65 152 ± 68 0.734 0.001
ACC time, min 111 ± 51 106 ± 49 0.157 0.002 104 ± 46 109 ± 50 0.410 0.002
Nadir Hct during CPB, % 22.9 ± 3.9 23.9 ± 3.6 <0.0001 0.071 23.4 ± 4.3 23.7 ± 3.7 0.305 0.019
ACC aortic cross-clamp, CABG coronary artery bypass graft, CPB cardiopulmonary bypass, Hct haematocrit, PCC prothrombin complex concentrates, SD
standard deviation
Continuous values are reported as mean and standard deviation; nominal variables are reported as counts and (percentages)
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confirmed that the PCC were associated with higher risk
of post-operative AKI (OR 1.70, 95 % CI 1.20–2.43, p =
0.003) and tended to be associated with a higher risk of
RRT (OR 3.35; 95 % CI 0.93–12.14, p = 0.065).
One-to-one propensity score–matched analysis re-
sulted in 225 pairs with similar baseline characteristics
and operative covariates (Tables 1 and 2). The area
under the ROC curve of the estimated propensity score
was 0.78 (95 % CI 0.75–0.81, p = 0.633 by Hosmer-
Lemeshow test). Post-match standardised differences for
the measured covariates, except hypertension, were <0.1
(most covariates were <0.05), suggesting substantial
covariate balance across groups (Fig. 1). Among these
matched pairs, the use of PCC was associated with a sig-
nificantly decreased post-operative blood loss (mean 836
vs. 935 ml, p < 0.0001) as well as lower risk of RBC
transfusion (84.0 % vs. 93.3 %, p = 0.002), transfusion of
more than 2 RBC units (50.7 % vs. 70.2 %, p < 0.0001)
and decreased amount of RBC units transfused (mean
3.4 vs. 5.2 U, p < 0.0001) (Table 3). The PCC group also
demonstrated a lower risk of resternotomy for bleeding,
but the difference did not reach statistical significance
(14.7 % vs. 18.7 %, p = 0.255). Among these matched
pairs, PCC was not associated with either a higher risk
of post-operative AKI (p = 0.683) or RRT (p = 0.403).
The incidence of thrombotic/thromboembolic events
such as stroke and transient ischemic attack was also
similar between patient groups (6.2 % vs. 4.0 %, p = 0.284,
and 1.3 % vs. 0.4 %, p = 0.336, respectively).
Propensity score–adjusted multivariate analysis showed
that PCC was associated with significantly lower risk of
RBC transfusions (OR 0.50, 95 % CI 0.31–0.80), decreased
Fig. 1 Standardized differences before and after propensity score matching comparing covariate values for patients with or without
PCC administration
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amount of RBC units (β, −1.42, 95 % CI −2.06 to −0.77)
and decreased risk of transfusion of more than 2 RBC
units (OR 0.53, 95 % CI 0.38–0.73). However, patients re-
ceiving PCC had an increased risk of post-operative AKI
(OR 1.44; 95 % CI 1.02–2.05) and RRT (OR 3.35, 95 % CI
1.13–9.90). No difference between groups was observed
with reference to hospital mortality (9.3 % vs. 8.4 %, OR
1.51, 95 % CI 0.84–2.72).
PCC dosage and outcome
Multivariate analysis including all baseline and operative
covariates of 291 patients who received PCC demon-
strated that the dose of PCC was not associated with any
of the main outcome end-points, other than bleeding
and use of blood products. In particular, the dose of
PCC was not associated with either post-operative AKI
(p = 0.424) or RRT (p = 0.99).
Group comparisons in the most recent series
To avoid any bias of including control patients who
underwent surgery several years before the introduction
of PCC in clinical use, only patients operated on from
2009 to 2013 were considered for further analysis of the
early outcome. We estimated a propensity score of this
subset of patients, and its area under the ROC curve was
0.72 (95 % CI 0.67–0.77, p= 0.176 by Hosmer-Lemeshow
test). One-to-one propensity score matching employing a
caliper width of 0.04 resulted in 123 pairs with similar base-
line characteristics and operative covariates. This analysis
showed that patients who received PCC had a similar out-
come compared with patients who received FFP (Additional
file 1: Table S1). Patients who received PCC had significantly
less blood loss and received fewer units of RBC.
Discussion
The present study demonstrates that the early use of PCC
instead of FFP was associated with a significant reduction
in blood transfusion requirements. However, PCC use was
also related to an increased risk of post-operative AKI.
PCC are a quite heterogeneous group of plasma-derived
products containing vitamin K–dependent clotting fac-
tors. Some contain only three clotting factors, such as the
ones commercially available in the United States and
Australia, whereas in Europe four-factor PCC are also
available [25]. Three-factor PCCs seem to be less powerful
than four-factor PCCs in neutralising the effect of war-
farin, probably due to the lack of factor VII [26]. Some of
the four-factor PCC are even more effective in correcting
the coagulopathy because they contain the activated factor
VII, like the factor VIII inhibitor bypassing activity
Table 3 Post-operative outcomes of patients with reference to PCC administration












In-hospital mortality 49 (7.2) 24 (8.2) 0.573 1.51, 0.84–2.72 19 (8.4) 21 (9.3) 0.740
Post-operative IABP 81 (11.9) 21 (7.2) 0.029 0.61, 0.35–1.09 32 (14.2) 17 (7.6) 0.023
Inotropes 559 (82.2) 217 (74.6) 0.007 0.74, 0.50–1.08 182 (80.9) 170 (75.6) 0.171
Vasopressors 177 (26.0) 92 (31.6) 0.075 1.18, 0.83–1.67 67 (29.8) 71 (31.6) 0.683
Peri-operative MI 35 (5.1) 14 (4.8) 0.827 1.22, 0.58–2.58 13 (5.8) 12 (5.3) 0.837
Stroke 38 (5.6) 20 (6.9) 0.439 1.19, 0.32–5.21 9 (4.0) 14 (6.2) 0.284
AKI 159 (23.4) 91 (31.3) 0.010 1.44, 1.02–2.05 60 (26.7) 68 (30.2) 0.403
RRT 8 (1.2) 9 (3.1) 0.037 3.35, 1.13–9.90 4 (1.8) 8 (3.6) 0.381
Post-operative AF 338 (49.7) 165 (56.7) 0.046 1.34, 0.97–1.84 124 (55.1) 136 (60.4) 0.252
Resternotomy for bleeding 114 (16.8) 42 (14.4) 0.365 0.95, 0.61–1.47 42 (18.7) 33 (14.7) 0.255
Blood loss, ml 908 ± 625 803 ± 1100 <0.0001 −96.5, −222.1 to −29.0 935 ± 583 836 ± 1226 <0.0001
RBC transfusion 619 (91.0) 243 (83.5) 0.001 0.50, 0.31–0.80 210 (93.3) 189 (84.0) 0.002
RBC transfusion, U 4.9 ± 4.5 3.4 ± 3.0 <0.0001 −1.42, −2.06 to −0.77 5.2 ± 4.3 3.4 ± 3.1 <0.0001
RBC transfusion >2 U 463 (68.1) 154 (52.9) <0.0001 0.53, 0.38–0.73 158 (70.2) 114 (50.7) <0.0001
Platelet transfusion 362 (53.2) 170 (58.4) 0.137 1.27, 0.92–1.75 123 (54.7) 133 (59.1) 0.341
Ventilation, h 82 ± 202 68 ± 99 0.160 −6.09, −34.12 to 21.95 73.2 ± 98.7 68 ± 95 0.871
ICU stay, h 125 ± 175 112 ± 122 0.191 −4.34, −1.49 to 0.63 128 ± 152 110 ± 118 0.954
In-hospital stay, days 13.2 ± 12.1 11.4 ± 7.7 0.589 −1.47, −3.20 to 0.27 14.1 ± 12.9 11.4 ± 7.9 0.115
MI myocardial infarction, AF atrial fibrillation, AKI acute kidney injury, CI confidence interval, IABP intra-aortic balloon pump, ICU intensive care unit, OR odds ratio,
PCC prothrombin complex concentrates, RBC red blood cells, RRT renal replacement therapy
Continuous values are reported as mean and standard deviation; nominal variables are reported as counts (percentages)
aβ value represents the β unstandardised coefficient of the linear regression analysis
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(FEIBA), but these products are routinely reserved for
patients with acquired autoimmune factor VIII deficiency
and they have only occasionally been used in complex
cardiac procedures [13, 25].
The number of indications for PCC use has increased
during the last few years. These products, initially devel-
oped for the treatment of haemophilia B, now have a
specific indication in cardiac surgery only when urgent
warfarin reversal is required [27, 28]. In a broader surgi-
cal context, the 2013 European Society of Anaesthesi-
ology guidelines confirmed the indication to use PCCs
in bleeding patients being given oral anti-coagulants
(grade 1B recommendation) and suggested the use PCCs
in patients not on warfarin treatment in the presence of
an elevated bleeding tendency and prolonged clotting
time (grade 2C recommendation) [29].
Since 2012, in agreement with our department of
haematology, a three-factor PCC has replaced FFP as
first-line treatment of bleeding patients following cardiac
surgery. The decision was based on a number of theoret-
ical advantages of PCC over FFP. The PCC seems to be
faster and more effective than FFP in controlling bleed-
ing, the concentration of clotting factors in PCC is on
average 25 times higher than FFP and PCC has been
shown to achieve the normalisation of the international
normalised ratio (INR) within 30 minutes of administra-
tion [26]. PCC is more readily available because it comes
lyophilized, can be quickly reconstituted and adminis-
tered in the operating theatre or in the ICU, and does
not require blood group specificity or defrosting. The
volume of PCC is typically less than FFP; therefore, they
can also be administered quickly in patients susceptible
to volume overload, thereby resulting in less haemodilu-
tion. On one hand, FFP is known to carry a significant
risk of viral infections and transfusion-related lung injur-
ies, whereas the use of PCC has not been associated with
such risks to date [30]. On the other hand, there are
documented risks associated with the use of PCC. In
two different animal models, PCC administration was
associated with an increased risk of thromboembolic
complications and disseminated intravascular coagula-
tion [31, 32].
The mortality associated with PCC use is not negli-
gible, The complications described include pulmonary
embolism, myocardial and renal infarction, stroke, limb
ischemia and deep vein thrombosis, although the overall
incidence of thromboembolic complications in patients
without haemophilia undergoing emergency reversal of
warfarin with PCC was low (3.8 %) [33, 34]. The accu-
mulation of factor II after repeated administration of
PCC could be the primary determinant of thrombotic
events [30]. Importantly, the risk may differ according to
the cause of coagulopathy. For patients requiring reversal
of oral anti-coagulants, plasma levels of the coagulation
inhibitor anti-thrombin may be normal, meaning that fac-
tor II levels can be restored to the normal range without
causing an imbalance. In contrast, patients with coagulop-
athy caused principally by haemodilution and/or con-
sumption are likely to have low levels of anti-thrombin as
well as factor II, meaning that administration of PCC
(with a great quantity of factor II and very small amounts
of anti-thrombin) may cause a pro-thrombotic imbalance.
There is a paucity of high-quality data on the use of
PCC in cardiac surgery. PCC seems to mitigate diffuse
bleeding following CPB in a porcine model [9]. A rando-
mised comparison of a four-factor PCC versus FFP in
patients undergoing cardiac surgery with INR >2.1
showed that PCC achieved normalisation of the INR
more quickly and in a higher percentage of patients than
FFP and that it was associated with a reduced use of
blood products [10]. In two further studies, PCC was
used as a second-line treatment in patients with severe
coagulopathy after bleeding could not be controlled with
FFP [12, 13]. Song et al. [13] successfully used FEIBA in
25 patients with life-threatening bleeding refractory to
conventional treatments following complex cardiac proce-
dures. In a non-randomised comparison of 150 patients
between a three-factor PCC and recombinant factor VIIa,
Tanaka et al. [12] reported the superiority of PCC as a sec-
ond-line treatment in patients with severe bleeding
following complex cardiac surgery. In another study,
by Görlinger and colleagues [14], the first-line admin-
istration of fibrinogen concentrate and PCC combined
with a point-of-care testing protocol was associated
with reduced blood transfusion requirements. Arnekian et
al. [11] presented the non-randomised comparison of
three treatments—four-factor PCC alone, PCC plus FFP
or FFP alone—in 77 bleeding patients following cardiac
procedures. In that study, a low dose of PCC was the most
effective in reducing chest tube drainage, reopening for
bleeding and blood product use, and no thromboembolic
event was noted. Nevertheless, the sample size of this
study was small, and the results were biased by the signifi-
cant differences among the three groups regarding their
pre-operative and intra-operative characteristics [11]. Re-
cently, Ortmann et al. [15], who enrolled 251 consecutive
patients undergoing pulmonary endarterectomy surgery,
observed that PCC was a valid alternative to FFP in pa-
tients with coagulopathy previously treated with warfarin.
Our present study has the largest number of patients
currently available in the literature who received a three-
factor PCC as first-line treatment for post-operative
bleeding following routine cardiac operations. These pa-
tients were compared with a series of 680 consecutive
patients who had surgery over the previous 7 years at
the same institution who received FFP because of bleed-
ing. Propensity score–matched analysis revealed that the
use of PCC as a first-line treatment for post-operative
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coagulopathy was effective in reducing bleeding and the
need of RBC transfusions. The incidence of platelet
transfusion was not different between the two groups,
given the very specific indications to prescribe this prod-
uct. These results were confirmed by the propensity ad-
justed multivariate analysis of the entire study population,
confirming that the use of PCC had a protective effect on
post-operative blood loss and RBC transfusion. Given the
broad time frame of the study (2005–2013) and the fact
that PCC was adopted only in 2012, a sub-analysis of pa-
tients who underwent surgery during a shorter study
period was performed to overcome this methodological
limitation and confirmed the overall findings of this study.
These results support, in practice, all the enunciated the-
oretical advantages of PCC over FFP, not only in terms of
readiness and rapidity of treatment but also because of the
significantly higher concentration of clotting factors ad-
ministered with it when compared with FFP.
The comparison of the two propensity-adjusted popu-
lations seems to show that the administration of PCC is
also safe. Indeed, no difference in terms of hospital mor-
tality was observed between the two groups. Nevertheless,
the incidence of renal complications was significantly
higher in the PCC group in the unadjusted comparison
and remained higher, although not statistically significant,
in the propensity score–matched analysis. However, PCC
was an independent predictive factor of AKI (1.4-fold) and
RRT (3.35-fold) in the propensity-adjusted multivariate
analysis. The possible reasons for this result could be sev-
eral. There is some evidence of the pro-thrombotic effects
of PCC and the risks of thromboembolic events such as
stroke and renal thrombosis associated with its use
[16, 18]. Despite these reports, it seems unlikely that
the underlying mechanism of AKI in our series could
be purely thromboembolic, given the absence of signifi-
cant differences in other thromboembolic complications
such as myocardial infarction or stroke. It is possible
to hypothesise that volume excess given with FFP
could somehow have a protective effect on kidney
function and that an exclusive use of PCC over FFP
in the context of a bleeding patient could lead to a
more hypovolemic balance. The use of vasopressors
in the PCC group was slightly higher but statistically sig-
nificant only in the non-adjusted comparison.
This study has limitations. The primary limitation is
its retrospective nature. It is a non-randomised study,
being a single-centre observational investigation based
on prospectively collected data, and a selection bias may
have been present, although we attempted to adjust for
baseline differences by assessing the role of PCC while
stratifying on the propensity score. Despite this careful
modelling approach, immeasurable factors may still
exist. Physician bias may have influenced PCC adminis-
tration, patient selection and dose, a difficulty inevitably
shared with other studies on the same subject [8–15].
The decision regarding use of FFP and PCC was predom-
inantly clinical and not necessarily based on thromboelas-
tography findings.
Conclusions
The results of this retrospective study indicate that, in
patients with excessive bleeding after cardiac surgery,
the use of PCC compared with FFP is associated with
decreased post-operative blood loss and RBC transfusion
requirements. However, PCC administration may pos-
sibly be associated with higher risk of post-operative
AKI. The potential benefits and harms associated with
the use of PCC in cardiac surgery should be investigated
in a randomised study.
Key messages
 Use of prothrombin complex concentrate (PCC)
compared with fresh frozen plasma is associated
with decreased post-operative blood loss and RBC
transfusion requirements.
 No increased risks of thrombogenic events were
associated with the use of PCC.
 PCC administration may be associated with a higher
risk of post-operative AKI.
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